Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICAIT DC Vaccine (Melanoma)
- Development stage
- Preclinical
- Lead developer
- ImmunoRestoration
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intranodal
01
Overview
ICAIT DC Vaccine (Melanoma) is an autologous dendritic cell-based immunotherapy being developed by ImmunoRestoration for the treatment of melanoma. Utilizing the company's proprietary ICAIT™ (Immune Priming via Dendritic Cell-based Immunization) platform, the vaccine consists of dendritic cells pulsed with HER-2 (Human epidermal growth factor receptor 2) antigens. The mechanism of action involves the presentation of these antigens to the patient's immune system to elicit a targeted anti-HER-2 adaptive immune response, specifically priming T-cells to recognize and eliminate HER-2-expressing tumor cells. As of early 2020, the program was in the preclinical stage of development.
- Other names
- ICAIT dendritic cell vaccine (Melanoma)HER-2 pulsed dendritic cell vaccine (Melanoma)
Beyond the preview
Go deeper on ICAIT DC Vaccine (Melanoma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICAIT DC Vaccine (Melanoma).